Advertisement
Screener

KALA BIO, INC. (KALA) Interest Expense Nonoperating

2.8 / 5 stars · 68/120 Roast Me

KALA BIO, INC. Interest Expense Nonoperating

KALA BIO, INC. (KALA) reported Interest Expense Nonoperating of $3.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.

Financial Statements › Expense Statement › Interest Expense

us-gaap:InterestExpenseNonoperating · last filed 2026-08-19

  • KALA BIO, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $141.00K, a 89.87% decline year-over-year.
  • KALA BIO, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $963.00K, a 34.84% decline year-over-year.
  • KALA BIO, INC. interest expense nonoperating for the quarter ending 2025-06-30 was $1.08M, a 25.86% decline year-over-year.
  • KALA BIO, INC. interest expense nonoperating for the quarter ending 2025-03-31 was $1.09M, a 25.02% decline year-over-year.
  • KALA BIO, INC. interest expense nonoperating for fiscal 2025 was $3.28M, a 43.35% decline from fiscal 2024.
  • KALA BIO, INC. interest expense nonoperating for fiscal 2024 was $5.78M, a 0.53% decline from fiscal 2023.
  • KALA BIO, INC. interest expense nonoperating for fiscal 2023 was $5.81M.
Period endInterest Expense Nonoperating 3 monthInterest Expense Nonoperating 6 monthInterest Expense Nonoperating 9 monthInterest Expense Nonoperating 12 month
2025-12-31$141.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$1.10M
derived: sum of 2 quarters · filed 2026-04-15
$2.19M
derived: sum of 3 quarters · filed 2026-08-19
$3.28M
10-K · filed 2026-04-15
2025-09-30$963.00K
10-Q · filed 2025-11-19
$2.04M
derived: sum of 2 quarters · filed 2026-08-19
$3.13M
10-Q · filed 2025-11-19
$4.53M
derived: sum of 4 quarters · filed 2026-08-19
2025-06-30$1.08M
10-Q · filed 2026-08-19
$2.17M
10-Q · filed 2026-08-19
$3.56M
derived: sum of 3 quarters · filed 2026-08-19
$5.04M
derived: sum of 4 quarters · filed 2026-08-19
2025-03-31$1.09M
10-Q · filed 2026-05-15
$2.48M
derived: sum of 2 quarters · filed 2026-05-15
$3.96M
derived: sum of 3 quarters · filed 2026-05-15
$5.42M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$1.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$2.87M
derived: sum of 2 quarters · filed 2026-04-15
$4.33M
derived: sum of 3 quarters · filed 2026-04-15
$5.78M
10-K · filed 2026-04-15
2024-09-30$1.48M
10-Q · filed 2025-11-19
$2.94M
derived: sum of 2 quarters · filed 2025-11-19
$4.39M
10-Q · filed 2025-11-19
$5.86M
derived: sum of 4 quarters · filed 2025-11-19
2024-06-30$1.46M
10-Q · filed 2025-08-08
$2.91M
10-Q · filed 2025-08-08
$4.38M
derived: sum of 3 quarters · filed 2025-08-08
$5.84M
derived: sum of 4 quarters · filed 2025-08-08
2024-03-31$1.46M
10-Q · filed 2025-05-14
$2.92M
derived: sum of 2 quarters · filed 2025-05-14
$4.38M
derived: sum of 3 quarters · filed 2025-05-14
$5.79M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$1.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$2.93M
derived: sum of 2 quarters · filed 2025-03-31
$4.34M
derived: sum of 3 quarters · filed 2025-03-31
$5.81M
10-K · filed 2025-03-31
2023-09-30$1.46M
10-Q · filed 2024-11-12
$2.87M
derived: sum of 2 quarters · filed 2024-11-12
$4.35M
10-Q · filed 2024-11-12
2023-06-30$1.41M
10-Q · filed 2024-08-06
$2.89M
10-Q · filed 2024-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
Moleculin Biotech, Inc. (MBRX)United States$0.011B
Theriva Biologics, Inc. (TOVX)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Dare Bioscience, Inc. (DARE)United States$0.011B
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92